Ki-ras and p53 mutations are early and late events, respectively, in urethane-induced pulmonary carcinogenesis in A/J mice

Molecular Carcinogenesis

Volumn 17, Issue 4, 1996, Pages 217-223

  Horio, Yoshitsugu ^a,c   Chen, Aaron ^a   Rice, Pamela ^b   Roth, Jack A ^a   Malkinson, Alvin M ^b   Schrump, David S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

A J mouse; Ki ras; p53; preneoplasia; tumor progression

Indexed keywords

PROTEIN P53; URETHAN;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; GENE MUTATION; LUNG CARCINOGENESIS; MOUSE; NONHUMAN; ONCOGENE K RAS; PRECANCER; PRIORITY JOURNAL; TUMOR GROWTH;

ADENOCARCINOMA; ADENOMA; ANIMALS; BASE SEQUENCE; CARCINOGENS; DISEASE PROGRESSION; EXONS; GENES, P53; GENES, RAS; HYPERPLASIA; LUNG NEOPLASMS; MICE; MICE, INBRED A; MOLECULAR SEQUENCE DATA; MUTATION; PRECANCEROUS CONDITIONS; TIME FACTORS; URETHANE;

ANIMALIA;

EID: 0030453289     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2744(199612)17:4<217::AID-MC5>3.0.CO;2-A     Document Type: Article

References (48)

1. Parkin DM. Lung cancer: Geographic epidemiology and its relation to tobacco. Abstract. Seventh International Symposium of the Foundation for the Promotion of Cancer Research pp. 12-13, 1994.
2. Cancer Facts and Figures. 1996. American Cancer Society, Inc., Atlanta, GA, 1996, p. 10.
3. Rusch V, Klimstra D, Linkov I, Dmitrovsky E. Aberrant expression of p53 or the epidermal growth factor receptor is frequent in early bronchial neoplasia, and coexpression precedes squamous cell carcinoma development. Cancer Res 55:1365-1372, 1995.
4. Sundaresan V, Ganly P, Hasleton P, et al. p53 and chromosome 3 abnormalities, characteristic of malignant lung tumours, are detectable in preinvasive lesions of the bronchus. Oncogene 7:1989-1997, 1992.
5. Kishimoto Y, Sugio K, Hung JY, et al. Allele-specific loss in chromosome 9p loci in preneoplastic lesions accompanying non-small-cell lung cancers. J Natl Cancer Inst 87(16): 1224-1229, 1995.
6. Thiberville L, Payne P, Vielkinds J, et al. Evidence of cumulative gene losses with progression of premalignant epithelial lesions to carcinoma of the bronchus. Cancer Res 55:5133-5139, 1995.
7. Chung GTY, Sundaresan V, Hasleton P, et al. Sequential molecular genetic changes in lung cancer development. Oncogene 11:2591-2598, 1995.
8. Sugio K, Kishimoto Y, Virmani A, et al. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res 54:5811-5815, 1994.
9. Malkinson AM. Primary lung tumors in mice: An experimentally manipulable model of human adenocarcinoma. Cancer Res (Suppl) 52:2670s-2676s, 1992.
10. You M, Candrian U, Maronpot RR, et al. Activation of the K-ras protooncogene in spontaneously occurring and chemically induced lung tumors of the strain A mouse. Proc Natl Acad Sci USA 86:3070-3074, 1989.
11. Schrump DS, Chen A, Consoli U. Inhibition of lung cancer proliferation by antisense cyclin D. Cancer Gene Ther, in press.
12. Oreffo VI, Malkinson AM. Decreased expression of MCC (mutated in colorectal cancer) and APC (adenomatous polyposis coli) tumor suppressor genes in urethane-induced mouse lung tumors. Abstract. Proc Annual Mtg Am Assoc Cancer Res 36:A1141, 1995.
13. Crist KA, Chen B, Creekmore AL, et al. Altered retinoblastoma gene expression and structure in mouse lung derived cell lines and solid tumors. Abstract. Proceedings of the Annual Meeting of the American Association for Cancer Research 34:A605,1993.
14. Festing MFW, Yang A, Malkinson AM. At least four genes and sex are associated with susceptibility to urethane-induced pulmonary adenomas in mice. Genet Res 64:99-106, 1994.
15. Ohmori H, AbeT, Hirano H, et al. Comparison of Ki-ras gene mutation among simultaneously occurring multiple urethan-induced lung tumors in individual mice. Carcinogenesis 13:851-855, 1992.
16. Rodenhuis S, Slebos RJC. Clinical significance of ras oncogene activation m human lung cancer. Cancer Res (Suppl) 52:2665s-2669s, 1992.
17. Horio Y, Takahashi T, Kuroishi T, et al. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res 53:1-4, 1993.
18. Orita M, Suzuki Y, Sekiya T, Hayashi K. Rapid and sensitive detection of point mutations and DNA polymorphisms using the polymerase chain reaction. Genomics 5:874-879, 1989.
19. Goodrow TL, Storer RD, Leander KR, et al. Murine p53 intron sequences 5-8 and their use in polymerase chain reaction/direct sequencing analysis of p53 mutations in CD-1 mouse liver and lung tumors. Mol Carcinog 5:9-15, 1992.
20. Horio Y, Suzuki H, Ueda R, et al. Predominantly tumor-limited expression of a mutant allele in a Japanese family carrying a germline p53 mutation. Oncogene 9:1231-1235, 1994.
21. Allen JW, Stoner GD, Pereira MA, et al. Tumorigenesis and genotoxicity of ethyl carbamate and vinyl carbamate in rodent cells. Cancer Res 46:4911-4915, 1986.
22. Chen B, Johanson L, Wiest JS, et al. The second intron of K-ras gene contains regulatory elements associated with mouse lung tumor susceptibility. Proc Natl Acad Sci USA 91:1589-1593, 1994.
23. Chen B, You L, Wang Y, et al. Allele-specific activation and expression of the k-ras gene in hybrid mouse lung tumors induced by chemical carcinogenesis. Carcinogenesis 15:2031-2035, 1994.
24. You M, Wang Y, Stoner G, et al. Parental bias of ki-ras oncogenes detected in lung tumors from mouse hybrids. Proc Natl Acad Sci USA 89:5804-5808, 1992.
25. Malkinson AM, You M. The intronic structure of cancer-related genes regulates susceptibility to cancer. Mol Carcinog 10:61-65, 1994.
26. Filmus J, Robles Al, Shi W, et al. Induction of cyclin D1 overexpression by activated ras. Oncogene 9:3627-3633, 1994.
27. Massey TE, Devereaux TR, Maronpot RR. High frequency of K-ras mutations in spontaneous and vinyl carbamate-induced lung tumors of relatively resistant B6CF1 (C57BL/6J×BALB/cJ) mice. Carcinogenesis 16:1065-1069, 1995.
28. Dragani T, Manenti G, Pierotti M. Genetics of murine lung tumors. Adv Cancer Res 67:83-112, 1995.
29. Kawano R, Nishisaka T, Takeshima Y, et al. Role of point mutation of the K-ras gene in tumorigenesis of B6C3F1 mouse lung lesions induced by urethane. Jpn J Cancer Res 86:802-810, 1995.
30. Belinsky SA, Devereux TR, Foley JF, et al. Role of the alveolar type II cell in the development and progression of pulmonary tumors induced by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in the A/J mouse. Cancer Res 52:3164-3173, 1992.
31. Wang X, Witschi H. Mutations of the Ki-ras protooncogene in 3-methylcholanthrene and urethane-induced and butylated hydroxytoluene-promoted lung tumors of strain A/J and SWR mice. Cancer Lett 91:33-39, 1995.
32. Li J, Beer DG. Kt-ras mRNA regulation in untransformed mouse lung cells. Mol Carcinog 8:193-201, 1993.
33. Foley JF, Anderson MW, Stoner GD. Proliferative lesions of the mouse lung: Progression studies in strain A mice. Exp Lung Res 17:157-168, 1991.
34. Re FC, Manenti G, Borrello MG, et al. Multiple molecular alterations in mouse lung tumors. Mol Carcinog 5:155-160, 1992.
35. Nuzum EO, Malkinson AM, Beer DG. Specific Ki-ras codon 61 mutations may determine the development of urethan-induced mouse lung adenomas or adenocarcinomas. Mol Carcinog 3:287-295, 1990.
36. Parada LF, Land H, Weinberg RA, et al. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. Nature 312:649-651, 1984.
37. Lu X, Park SH, Thompson TC, et al. Ras-induced hyperplasia occurs with mutation of p53, but activated ras and myc together can induce carcinoma without p53 mutation. Cell 70:153-161, 1992.
38. Finney RE, Bishop JM. Predisposition to neoplastic transformation caused by gene replacement of H-ras 1. Science 260:1524-1527, 1993.
39. Soussi T, Caron de Fromentel C, May P. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5:945-952, 1990.
40. Pavletich NP, Chambers KA, Pabo CO. The DNA-binding domain of p53 contains the four conserved regions and the major mutation hot spots. Genes Dev 7:2556-2564, 1993.
41. Cho Y, Gorina S, Jeffrey PD, et al. Crystal structure of a p53 tumor suppressor-DNA complex: Understanding tumorigenic mutations. Science 265:346-355, 1994.
42. Chen B, Liu L, Castonguay A, et al. Dose-dependent ras mutation spectra in N-nitrosodiethylamine induced mouse liver tumors and 4-(methylnitrosamino)-1-(3-pyridyl)-1 -butanone induced mouse lung tumors. Carcinogenesis 14:1603-1608, 1993.
43. 6-methylguanine DMA adduct levels and Ki-ras activation in lung tumors from resistant and susceptible mouse strains. Mol Carcinog 8:177-185, 1993.
44. Hegi ME, Soderkvist P, Foley JF, et al. Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis 14:803-810, 1993.
45. Ohshima S, Shimizu Y, Takahama M. Detection of c-Ki-ras gene mutation in paraffin sections of adenocarcinoma and atypical bronchioloalveolar cell hyperplasia of human lung. Virchows Arch 424:129-134, 1994.
46. Westra WH, Baas IO, Hruban RH, et al. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res 56:2224-2228, 1996.
47. Kerr KM, Carey FA, King G, et al. Atypical alveolar hyperplasia: Relationship with pulmonary adenocarcinoma, p53, and c-erbB-2 expression. J Pathol 174:249-256, 1994.
48. Kitamura H, Kameda Y, Nakamura N, et al. Proliferate potential and p53 overexpression in precursor and early stage lesions of bronchioloalveolar lung carcinoma. Am J Pathol 146:876-887, 1995.